Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Patient information Receiving a BRCA1 and BRCA2 test result that identifies a variant of unknown significance (VUS) Information sheet for patients with cancer You had a BRCA1 and BRCA2 gene test because you have had cancer. The test result has shown that you have a gene variant in either the BRCA1 or BRCA2 gene that requires further evaluation. A variant is simply a change in a gene which may not have been seen before and so it is unclear whether or not it is related to your cancer. It is possible that this variant occurs in the general population and is not linked to your cancer diagnosis. Variants in the BRCA1 and BRCA2 genes are common, and most do not cause cancer. In order to look into this variant further your cancer team will have referred you to see one of the clinical genetics team. What does this result mean for my relatives? It is not possible to offer any further genetic testing to relatives. All women are eligible to have mammograms from 47 years in the National Breast Screening Programme. Depending on the family history, some women may be eligible for mammograms from 40 years, even if there is no BRCA1 or BRCA2 mutation in the family. There is currently no known effective form of ovarian screening. If a woman has more than one relative with ovarian cancer, removal of the ovaries is sometimes considered. If this is the case in your family, please discuss this further with your cancer team. If any of your relatives wish to discuss their own risk of cancer further, they should speak with their GP who can refer them for further discussions at their local family history clinic. If you have any further questions in relation to your ongoing cancer treatment, please contact your cancer team. MCG IS4 v1 Genetics Unit Page 1 of 1 Reviewed: May 2015Planned review: May 2017